18 patents
Utility
Methods of Treating Iron Overload
21 Dec 23
The invention features methods of treating iron overload in a subject by administering BMP or hepcidin inhibitors, such as ALK2 inhibitors.
Jasbir S. SEEHRA, Jennifer LACHEY, Christopher R. ROVALDI, Claudia ORDONEZ
Filed: 27 Apr 23
Utility
Methods of Treating Cardiovascular-related Disease
14 Dec 23
The invention features methods of treating or preventing the development of a cardiovascular-related disease by administering to the subject a BMP inhibitor or a hepcidin inhibitor, such as an ALK2 inhibitor.
Jasbir S. SEEHRA, Jennifer LACHEY, Claudia ORDONEZ, Christopher R. ROVALDI
Filed: 26 Apr 23
Utility
Methods of Treating Lymphopenia
23 Nov 23
The invention features methods of treating or preventing lymphopenia in a subject treated with a BMP inhibitor or a hepcidin inhibitor, such as an ALK2 inhibitor, by co-administering an iron supplement with the inhibitor, and methods of treating a subject who has or is at risk of developing a disease or condition that can be treated with a BMP inhibitor or a hepcidin inhibitor, such as an ALK2 inhibitor, by administering to the subject a BMP inhibitor or a hepcidin inhibitor and an iron supplement.
Jasbir S. SEEHRA, Jennifer LACHEY, Christopher R. ROVALDI, Claudia ORDONEZ
Filed: 27 Apr 23
Utility
Methods of Using Activin Receptor Type II Variants
2 Nov 23
The invention features polypeptides that include an extracellular ActRII variant, such as an ActRIIA variant, ActRIIB variant, or ActRII chimera.
Jasbir S. SEEHRA, Christopher R. ROVALDI
Filed: 30 Mar 23
Utility
Nucleic acid molecules encoding activin receptor type IIA variants
8 Aug 23
The invention features polypeptides that include an extracellular ActRIIa variant.
Jasbir S. Seehra, Jennifer Lachey
Filed: 24 May 21
Utility
Methods of Using Activin Receptor Type Iib Variants
23 Mar 23
The invention features polypeptides that include an extracellular ActRIIB variant.
Jasbir S. SEEHRA, Jennifer LACHEY, Elissa FURUTANI
Filed: 15 Sep 22
Utility
Activin Receptor Type II Chimeras and Methods of Use Thereof
16 Mar 23
The invention features polypeptides that include an extracellular ActRII chimera.
Jasbir S. SEEHRA, Jennifer LACHEY, Claire TSENG, Jason O'NEILL, Henning THØGERSEN, Elissa FURUTANI
Filed: 15 Sep 22
Utility
Methods of Using ALK2 Inhibitors
22 Dec 22
The invention relates to methods of treating multiple osteochondroma and anemia resulting from iron imbalance using small molecule ALK2 inhibitors.
Jasbir S. SEEHRA, Jennifer LACHEY, Elissa FURUTANI
Filed: 30 Apr 21
Utility
Activin receptor type IIa variants and methods of use thereof
1 Nov 22
The invention features polypeptides that include an extracellular ActRlla variant.
Jennifer Lachey, Jasbir S. Seehra
Filed: 9 Nov 18
Utility
Activin Receptor Type Iia Variants and Methods of Use Thereof
9 Sep 21
The invention features polypeptides that include an extracellular ActRIIa variant.
Jasbir S. SEEHRA, Jennifer LACHEY
Filed: 24 May 21
Utility
ALK2 Antibodies and Methods of Use Thereof
19 Aug 21
The invention features ALK2 antibodies and antigen binding fragments thereof (e.g., ALK2 binding fragments).
Jasbir S. SEEHRA, Jennifer LACHEY
Filed: 22 Apr 21
Utility
Activin receptor type IIa variants and methods of use thereof
17 Aug 21
The invention features polypeptides that include an extracellular ActRlla variant.
Jasbir S. Seehra, Jennifer Lachey
Filed: 9 Nov 17
Utility
Crystal Forms of an ALK2 Inhibitor
5 Aug 21
The invention relates to crystalline forms of an ALK2 inhibitor, methods of their preparation, and related pharmaceutical preparations thereof.
Sarah BETHUNE, Krista DIAZ, Catherine A. EVANS
Filed: 23 Apr 21
Utility
Activin receptor type IIA variants and methods of use thereof
25 May 21
The invention features polypeptides that include an extracellular ActRIIa variant.
Jasbir S. Seehra, Jennifer Lachey
Filed: 9 Nov 17
Utility
Activin Receptor Type Iia Variants and Methods of Use Thereof
25 Feb 21
The invention features polypeptides that include an extracellular ActRIIA variant.
Jasbir S. SEEHRA, Jennifer LACHEY
Filed: 6 Nov 20
Utility
Activin Receptor Type Iia Variants and Methods of Use Thereof
4 Feb 21
The invention features polypeptides that include an extracellular ActRIIa variant.
Jennifer LACHEY, Jasbir S. SEEHRA
Filed: 9 Nov 18
Utility
Activin Receptor Type Iib Variants and Methods of Use Thereof
30 Dec 20
The invention features polypeptides that include an extracellular ActRIIB variant.
Jasbir S. SEEHRA, Jennifer LACHEY
Filed: 8 Jul 20
Utility
Activin Receptor Type Iia Variants and Methods of Use Thereof
13 Nov 19
The invention features polypeptides that include an extracellular ActRIIa variant.
Jasbir S. SEEHRA, Jennifer LACHEY
Filed: 8 Nov 17
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first